Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has earned an average recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat.com reports.
NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...
Oppenheimer analyst Francois Brisebois maintained a Buy rating on Mind Medicine (MNMD – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $7.40.
Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024 has been a transformational year for MindMed.
Mind Medicine (MindMed) Stock Performance Mind Medicine (MindMed) stock opened at $7.16 on Friday. The company has a 50 day moving average price of $7.15 and a 200-day moving average price of $6. ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...